MK-3475-028; Phase IB Study of MK-3475 in Subjects with Select Advanced Solid Tumors
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to test the safety and tolerability of the research study drug, MK-3475.
Description
This study will assess the efficacy and safety of pembrolizumab administered to participants with incurable advanced biomarker-positive solid tumors that have not responded to current therapy or for which current therapy is not appropriate. The hypothesis is that administration of pembrolizumab to participants with some types of solid tumors will result in a clinically meaningful response rate.
Details
| Condition | Solid Tumor |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX3731 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.